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The aims of this article are to review the evidence regarding the use of non-vitamin
K oral anticoagulants (NOACs) for secondary stroke prevention as compared to vita-
min K antagonists in patients with atrial fibrillation (AF) and in patients with embolic
strokes of uncertain source (ESUS), and when to initiate or resume anticoagulation
after an ischaemic stroke or intracranial haemorrhage.
Four large trials compared NOACs with warfarin in patients with AF. In our meta-
analyses, the rate of all stroke or systemic embolism (SE) was 4.94% with NOACs
vs. 5.73% with warfarin. Among the patients with AF and previous transient
ischaemic attack or ischaemic stroke, the rate of haemorrhagic stroke was halved
with a NOAC vs. warfarin, and the rate of major bleeding was 5.7% with a NOAC
vs. 6.4% with warfarin. There was no significant difference in mortality. In a trial
comparing apixaban with aspirin in patients with AF, the rate of stroke or SE was
2.4% at 1 year with apixaban vs. 9.2% at 1 year with aspirin and the rates of major
bleeding were 4.1% with apixaban vs. 2.9% with aspirin. Data from registries con-
firmed the results from the randomized trials. Initiation or resumption of anticoa-
gulation after ischaemic stroke or cerebral haemorrhage depends on the size and
severity of stroke and the risk of recurrent bleeding. Two large trials tested the
hypothesis that NOACs are more effective than 100mg aspirin in patients with
ESUS. Neither trial showed a significant benefit of the NOAC over aspirin.
In the meta-analysis, the rate all stroke or SE was 4.94% with NOACs vs. 5.73% with
warfarin and the rate of haemorrhagic stroke was halved with a NOAC. The four
NOACs had broadly similar efficacy for the major outcomes in secondary stroke
prevention.
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Introduction
Patients with atrial fibrillation (AF) have a high risk of
stroke. The risk of stroke is particularly high in patients
with AF who have a history of transient ischaemic attack
(TIA) or stroke.1
Oral anticoagulation with vitamin K antagonists such
as warfarin is highly effective in preventing recurrence
of stroke with a relative risk reduction of 60–70%.2
However, stroke prevention with warfarin has a number
of practical limitations such as a narrow therapeutic
window, interaction with food and other drugs, and the
need to monitor coagulation levels regularly. Non-
vitamin K oral anticoagulants (NOACs) such as apixaban,
dabigatran, edoxaban, or rivaroxaban do not require
regular monitoring of coagulation parameters. The
NOACs have no interaction with food and relatively mi-
nor interactions with other drugs.
Non-vitamin K oral anticoagulants have been compared
with warfarin in four large randomized trials in patients
with AF.3–6 All trials included subgroups of patients with
previous TIA or an ischaemic stroke.7–10 The results of these
subgroups are summarized and evaluated below. The pri-
mary endpoint in all studies comparing NOACs with warfa-
rin in patients with AF was stroke and systemic embolism
(SE). However, this endpoint includes an efficacy endpoint
of the prevention of ischaemic stroke and a complication of
anticoagulation, cerebral haemorrhage.
Non-vitamin K oral anticoagulants for
secondary prevention in patients with atrial
fibrillation and prior stroke or transient
ischaemic attack
The efficacy and safety of dabigatran, rivaroxaban, apixa-
ban, and edoxaban have been compared with warfarin for
stroke prevention in AF in four large phase 3 clinical trials:
ARISTOTLE,3 RE-LY,4 ROCKET-AF,5 and ENGAGE-AF.6 All trials
included a substantial number of AF patients with a history
of prior stroke or TIA (Table 1).
Apixaban vs. warfarin
The ARISTOTLE (Apixaban for Reduction in Stroke and
Other Thromboembolic Events in Atrial Fibrillation) trial
compared apixaban 5mg twice daily with warfarin [target
Internatiiona Normalized Ratio (INR) 2.0–3.0].3 Patients
with impaired renal function [serum creatinine >2.5mg/
dL (221lmol/L) or creatinine clearance<25mL/min], pre-
vious intracranial haemorrhage (ICH), or any stroke within
7days before randomization were excluded. Patients who
fulfilled two out of three criteria received a lower dose of
apixaban of 2.5mg twice a day: elderly (80 years or older),
or low bodyweight (60 kg or lighter), or a serum creatinine
of 133lmol/L (1.5mg/dL) or greater.3
Among the 3436 patients with AF and a previous ischae-
mic stroke or TIA who were enrolled in the ARISTOTLE trial
(Table 1), the relative effects of apixaban vs. warfarin
were consistent with the relative effects of apixaban vs.
warfarin in the 14 765 AF patients without previous stroke
or TIA for major outcomes.8 Among the 3436 patients with
prior stroke or TIA, the rate of stroke or SE was 2.46%/year
with apixaban vs. 3.24%/year with warfarin [hazard ratio
(HR) 0.76, 95% confidence interval (CI) 0.56–1.03].8 Among
patients with prior stroke or TIA, the rate ofmajor bleeding
was 2.84%/year with apixaban vs. 3.91%/year warfarin (HR
0.73, 0.55–0.98).8
Dabigatran vs. warfarin
The RE-LY (Randomized Evaluation of Long-term anticoagu-
lant therapY) trial was a three-armed trial that compared
two doses of dabigatran (110mg twice a day or 150mg
twice a day) to standard dose-adjusted warfarin (target
INR 2.0–3.0) in 18 113 patients with AF.4 Patients were ex-
cluded if they had poor renal function (creatinine clear-
ance of <30mL/min) or a stroke within 14days of
randomization. A total of 3623 (20%) patients with AF had a
history of ischaemic stroke or TIA more than 14days before
randomization, of whom 1233 were randomized to dabiga-
tran 150mg b.i.d., 1195 to dabigatran 110mg b.i.d., and
1195 to warfarin (Table 1).
The relative effects of dabigatran vs. warfarin in the
3623 patients with previous stroke or TIA were consistent
Table 1 Patients with atrial fibrillation and prior TIA or stroke in randomized trials: baseline data
ARISTOTLE AVERROES RE-LY ROCKETAF ENGAGEa
Apixaban Warfarin Apixaban Aspirin Dabigatran
110
Dabigatran
150
Warfarin Rivaroxaban Warfarin Edoxabanb Warfarin
N 1694 1742 390 374 1195 1233 1195 3754 3714 1976 1991
Age (years) 70.1 71.7 70.2 70.8 70.4 71 71 70
Females 37% 44% 36% 38% 42% 39% 39% 38%
Hypertension 83% 81% 77% 77% 76% 85% 85% 86%
Diabetes 26% 20% 22% 24% 21% 25% 24% 27%
CHADS 3 92% 93% 90% 90% 89% NA NA 67%
Aspirinc 31% 28% 40% 40% 42% 38% 38% 28%
Adapted from Diener et al.11
Dabigatran; 110¼ 110mg twice daily; 150¼ 150mg twice daily.
aData not reported by treatment group.
bEdoxaban 60 mg or 30 mg in patients fulfilling the dose reduction criteria.
cAspirin intake at baseline.
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with the effects of dabigatran vs. warfarin in the 14 490
patients without previous stroke or TIA for all major effi-
cacy and safety outcomes.7 Among the 3623 patients with
AF and prior stroke or TIA, the rate of stroke or SE was
2.32%/year with dabigatran 110mg vs. 2.78%/year warfa-
rin [risk ratio (RR) 0.84, 0.58–1.20], and 2.07%/year with
dabigatran 150mg vs. 2.78%/year warfarin (RR 0.75, 0.52–
1.08).7 Among patients with prior stroke or TIA, the rate of
major bleeding was 2.74%/year with dabigatran 110mg vs.
4.15%/year warfarin (RR 0.66, 0.48–0.90) and 4.15%/year
with dabigatran 150mg vs. 4.15%/year warfarin (RR 1.01,
0.77–1.34).7
Rivaroxaban vs. warfarin
The oral factor Xa inhibitor rivaroxaban was compared
with warfarin in ROCKET-AF [Rivaroxaban—Once daily oral
direct factor Xa inhibition Compared with vitamin K antag-
onism (target INR 2.0–3.0) for prevention of stroke and
Embolism Trial in Atrial Fibrillation].5 Patients with very re-
cent TIA within 3 days, acute stroke within 14days, or se-
vere disabling stroke within 3months of randomization,
were excluded.9 The study population in ROCKET-AF was at
high risk of stroke; 55% of patients had a previous ischaemic
stroke or TIA, and 90% had either a previous stroke or TIA,
or three or more risk factors for stroke (Table 1). Patients
were randomly assigned to receive fixed-dose rivaroxaban
(20mg daily, or 15mg daily in patients with a creatinine
clearance of 30–49mL per minute) or adjusted-dose warfa-
rin (target INR 2.0–3.0). The relative effects of rivaroxaban
vs. warfarin in the 7468 patients with previous stroke or
TIAwere consistent with the effects of rivaroxaban vs. war-
farin in the 6796 patients without previous stroke or TIA for
major outcomes.9 Among the 7468 patients with prior
stroke or TIA, the rate of stroke or SE was 2.79%/year with
rivaroxaban vs. 2.96%/year warfarin (HR 0.94, 0.77–1.16).9
Among patients with prior stroke or TIA, the rate of major
bleeding was 3.13%/year with rivaroxaban vs. 3.22%/year
warfarin (HR 0.97, 0.79–1.19).9
Edoxaban vs. warfarin
The Effective Anticoagulation with Factor Xa Next
Generation in Atrial Fibrillation–Thrombolysis in Myocardial
Infarction 48 (ENGAGE AF-TIMI 48) trial was a three-group,
randomized, double-blind, double-dummy trial comparing
two once-daily regimens of edoxaban [higher-dose edoxa-
ban (60mg once daily), or lower-dose edoxaban (30mg
once daily)] with adjusted-dose warfarin (INR 2.0–3.0) in
21 105 patients with moderate-to-high-risk AF (median
follow-up, 2.8 years).6 Patients were excluded if they had a
stroke within 30days before randomization. The 60mg
dose of edoxabanwas halved if any of the following charac-
teristics were present at the time of randomization or dur-
ing the study: estimated creatinine clearance of 30–50mL
per minute, a bodyweight of 60kg or less, or the concomi-
tant use of verapamil or quinidine (potent P-glycoprotein
inhibitors). A total of 5973 (28.3%) patients had a previous
ischaemic stroke or TIA, of whom 1976 were allocated
higher dose edoxaban, and 1991 warfarin.10 As only the
higher dose edoxaban is approved for use by regulatory
authorities worldwide, the results below reflect the
comparison of high dose edoxaban 60mg once daily vs.
warfarin. Among the 3967 patients with prior stroke or TIA,
the rate of stroke or SE was 2.44%/year with higher-dose
edoxaban vs. 2.85%/year warfarin (HR 0.86, 0.67–1.09).10
Among the 3967 patients with prior stroke or TIA, the rate
of major bleeding was 3.25%/year with higher-dose edoxa-
ban vs. 3.86%/year warfarin (HR 0.84, 0.67–1.06).10
Meta-analyses of major trials of non-vitamin
K oral anticoagulants vs. warfarin in patients
with prior stroke or transient ischaemic
attack
Meta-analyses of all 71 683 participants enrolled in the RE-
LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials,
included 17 299 (24%) patients with AF and a history of prior
stroke or TIA.12,13 Adding the group of patients treated
with a low dose of dabigatran resulted in 19 689 patients
with AF and previous TIA or ischaemic stroke. The rate of
stroke or SE, over a median follow-up ranging from 1.8 to
2.8 years, was 4.94% with a NOAC vs. 5.73% with warfarin
(RR 0.86, 0.77–0.97). Figure 1A shows a forest plot of the
fourmajor clinical trials of the effect of NOACs vs. warfarin
on stroke or SE. There was no significant difference in the
relative effects of NOACs vs. warfarin on ischaemic stroke
(RR 0.98, 0.85–1.13) (Figure 1B). The rate of haemorrhagic
stroke was halved with a NOAC vs. warfarin (RR 0.45, 0.33–
0.61) (Figure 1C). Among patients with AF and previous TIA
or ischaemic stroke, the rate of major bleeding was 5.71%
with a NOAC vs. 6.43% warfarin (RR 0.86, 0.77–0.96)
(Figure 1D). Among patients with previous TIA or ischaemic
stroke, there was a non-significant trend to a lower rate of
death from any cause with a NOAC vs. warfarin (RR 0.89,
0.82–0.97) (Figure 1E).
Apixaban vs. aspirin
The AVERROES (Apixaban vs. Aspirin to Reduce the Risk of
Stroke) study compared apixaban (5mg twice daily) vs. as-
pirin (81–324mg per day) in patients with AF who were
thought to be unsuitable or unwilling to receive a vitamin K
antagonist.14 The reasons for unsuitability for a vitamin K
antagonist varied, but most (>70%) were related to issues
with INR monitoring, INR instability, and patient refusal to
take vitamin K antagonists. Stroke within the previous
10 days was an exclusion criteria.
The AVERROES trial showed overall that in patients with
AF who were unable or unwilling to take a vitamin K antag-
onist, apixabanwas more effective than aspirin for the pre-
vention of stroke and systemic embolic events (1.6% per
year apixaban vs. 3.7% per year aspirin HR 0.45, 0.32–0.62;
P< 0.001), but it was also as safe as aspirin for major
bleeding (1.4% per year apixaban vs. 1.2% aspirin; HR 1.13,
0.74–1.75; P¼ 0.57) and ICH (0.4% per year apixaban vs.
0.4% per year aspirin; HR 0.85, 0.38–1.90; P¼ 0.69).
The relative effects of apixaban vs. aspirin in the 764
patients with previous stroke or TIA were consistent with
the effects of apixaban vs. aspirin in the 4832 patients
without previous stroke or TIA.15 Among 764 patients with
previous stroke or TIA, the rate of stroke or SE was 2.39% at
1 year with apixaban vs. 9.16% at 1-year aspirin (HR 0.29,
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Figure 1 (A) Forest plot of the effect of non-vitamin K oral anticoagulants vs. warfarin on stroke or systemic embolism. (B) Forest plot of the effect of
non-vitamin K oral anticoagulants vs. warfarin on ischaemic stroke. (C) Forest plot of the effect of non-vitamin K oral anticoagulants vs. warfarin on hae-
morrhagic stroke. (D) Forest plot of the effect of non-vitamin K oral anticoagulants vs. warfarin on major bleeding. (E) Forest plot of the effect of non-vi-
tamin K oral anticoagulants vs. warfarin on death from any cause. Initiation or resumption of antithrombotic therapy after transient ischaemic attack or
ischaemic stroke. AF, atrial fibrillation; NOAC, non-vitmain-K oral anticoagulant; VKA, vitamin-K antagonist.
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0.15–0.60).15 Among 764 patients with previous stroke or
TIA, the rates of major bleeding were: 4.1% at 1-year apix-
aban vs. 2.89% at 1-year aspirin (HR 1.28, 0.58–2.82).15
Indirect comparison analysis
The efficacy and safety of one NOAC against another can
only be definitively answered by a head-to-head random-
ized clinical trial (RCT). As no such trials have been per-
formed, a number of indirect comparison analyses have
been performed. For example, in secondary prevention, the
comparison of apixaban with dabigatran (110mg and 150mg
twice daily) showed a lower risk of myocardial infarction
(HR 0.39, 95% CI 0.16–0.95) for apixaban compared to dabi-
gatran 150mg twice daily.16 No significant differences in ef-
ficacy and most safety endpoints were found between
apixaban and dabigatran 150mg compared to rivaroxaban.
When comparing 110mg b.i.d. dabigatran and rivaroxaban,
there was less haemorrhagic stroke (HR 0.15, 0.03–0.66),
vascular death (0.64, 0.42–0.99), severe bleeding (0.68,
0.47–0.99), and intracranial bleeding (0.27, 0.10–0.73) with
dabigatran. No differenceswere found for the other efficacy
endpoints and the risk of bleeding.
In summary, apixaban, rivaroxaban, and dabigatran ap-
pear to have broadly similar efficacy for the major end-
points in secondary prevention, although the endpoints of
haemorrhagic stroke, vascular death, major bleeding, and
ICH were less frequent with dabigatran 110mg twice daily
than with rivaroxaban.
Data from registries
Data from RCTs are the best evidence when comparing the
efficacy and safety of an intervention. Following the RCT,
the NOACs are licensed and used in everyday clinical prac-
tice, so-called ‘real world’ registries, which have provided
much data comparing NOACs to warfarin, and to each
other. Some have been based on claims datasets, while
large prospective registries have also been published.
The largest of the retrospective claims datasets pub-
lished was the ARISTOPHANES study (Anticoagulants for
Reduction in Stroke: Observational Pooled Analysis on
Health Outcomes and Experience of Patients) which used
multiple data sources to compare stroke/SE and major
bleeding (MB) among a large number of non-valvular AF
patients on NOACs or warfarin.17 The authors found that af-
ter propensity score matching, the NOACs had lower rates
of stroke/SE and variable comparative rates of MB vs. war-
farin, and subgroup analyses on patients with prior stroke/
SEwere generally consistent with themain results.
The study by Coleman et al.18 used MarketScan claims in
the USA from January 2012 to June 2015 to analyse adults
with newly initiated on oral anticoagulation and non-
valvular AF and a history of previous ischaemic stroke/TIA.
Data were analysed after 1:1 propensity score matching for
apixaban vs. warfarin (n¼ 2514), dabigatran vs. warfarin
(n¼ 1962), and rivaroxaban vs. warfarin (n¼ 5208). After a
short mean observation time of 0.5 years, neither apixaban
nor dabigatran reduced the combined primary endpoint of
ischaemic stroke or ICH (HR 0.70, 95% CI 0.33–1.48 and HR
0.53, 95% CI 0.26–1.07). Rivaroxaban reduced the com-
bined endpoint of ischaemic stroke or ICH (HR 0.45, 95% CI
0.29–0.72) without an effect on major bleeding (HR 1.07,
95% CI 0.71–1.61).
Using the Korean National Health Insurance Service claims
database. Park et al.19 investigated the effectiveness and
safety of NOACs for secondary prevention in 61 568 patients
with AF. Compared with warfarin, NOACs were associated
with lower risks of recurrent stroke (HR 0.67, 95% CI 0.62–
0.72), major bleeding (HR 0.73, 95% CI 0.66–0.80), compos-
ite outcome (HR 0.69, 95% CI 0.65–0.73), and mortality.
There was a consistent trend of improved outcomes in the
subgroups of patients with severe, disabling, and recent
stroke. Similar data were published from Taiwan’s National
Health Insurance Research Database, where the reduced
risks of thromboembolism and major bleeding for the four
direct oral anticoagulants over warfarin persisted in AF pa-
tients with either primary or secondary stroke prevention.20
The PROSPER registry collected a cohort of Medicare
patients with AF in the USA who had a history of ischaemic
stroke21: 11 662 survivors of acute ischaemic stroke with a
median age of 80years were identified, of which 4041
(34.7%) patients were discharged with a NOAC and 7621 with
warfarin. Patients on NOACs were less likely to experience
major adverse cardiovascular events [adjusted HR (aHR)
0.89, 99% CI 0.83–0.96], and mortality was also reduced
(aHR 0.88, 95% CI 0.82–0.95; P < 0.001). Concerning bleed-
ing complications, haemorrhagic strokes (aHR 0.69, 95% CI
0.50–0.95; P ¼ 0.02), and hospitalizations due to bleeding
(aHR 0.89, 95% CI 0.81–0.97; P ¼ 0.009) were reduced
amongst those taking NOACs. The risk of gastrointestinal
bleeding, however was increased (aHR 1.14, 95% CI 1.01–
1.30; P ¼ 0.03). The discrepancy between the two registry
data could be due to the differences in mean age, which was
73years in the Coleman et al. study and 80years in
PROSPER, as well as the short follow-up in the former study.
Recommendations from guidelines
The guidelines of the European Society of Cardiology from
2016 recommend NOACs in preference to vitamin-K antag-
onists (VKAs) or aspirin in patients with AF and a previous
stroke (Class I, level B).22 The guidelines of the European
Stroke Organization recommend in patients with non-
valvular AF and previous ischaemic stroke or TIA, non-
vitamin K antagonist oral anticoagulants over VKAs for
secondary prevention of all events (quality of evidence:
high, strength of recommendation: strong).23 The 2017
consensus of the Asia Pacific Heart Rhythm society states,
that NOACs are preferred over VKA in Asian patients with a
history of ischaemic stroke or TIA.24
Initiation or resumption of anticoagulation
with non-vitamin K oral anticoagulants after
ischaemic stroke or intracranial bleeding
Despite available guideline recommendations, the optimal
time for administering anticoagulation therapy in acute car-
dioembolic stroke remains unclear. Guidelines from the
European Society of Cardiology (ESC) for themanagement of
AF recommend that in patients who suffer a moderate-to-
severe ischaemic stroke while on anticoagulation, this
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treatment should be interrupted for 3–12days to allow a
multidisciplinary assessment of acute stroke and bleeding
risk.25 The use of NOACs following a cardioembolic stroke
has been assessed in several observational studies. The
SAMURAI-NVAF study demonstrated that following NOAC ini-
tiation, within a median of 4days post-stroke, no ICH was
observed.26 Furthermore, in another observational study, no
significant difference in recurrent ischaemic events was ob-
served with post-stroke NOAC initiation, either less than or
equal to 7days or greater than 7days following the initial
event (P¼ 0.53).27 Early recurrences and major bleeding
events (within 90days) and the timing of these events in
patients with an acute ischaemic stroke and AFwho received
a NOAC following the initial event were assessed in the pro-
spective observational multicentre RAF-DOAC study. An
early recurrent event occurred in 32 patients (2.8%) andma-
jor bleeding in 27 patients (2.4%). The composite rate of re-
currence and major bleeding was 12.4% for patients
initiating NOACs less than or equal to 2days after the acute
stroke, 2.1% for those initiating between days 3 and 14, and
9.1% for those initiating NOACs greater than 14days after
the initial stroke. The combined rate of recurrent and major
bleeding was 5% in patients treated with NOACs following an
acute stroke.28 An individual patient data analysis including
4912 patients treated with oral anticoagulation after recent
cerebral ischaemia related to AF revealed the following ma-
jor findings: First, treatment with NOACs commenced a me-
dian of 5days after the index event has a lower risk of
adverse outcomes compared to treatment with VKA; sec-
ond, this benefit is mainly attributed to lower risks of ICH;
and, third, the benefit is consistent across subgroups.29
Currently, several RCTs are investigating the risks and
benefits of the early start of DOAC (Switzerland: ELAN
ClinicalTrials.gov Identifier: NCT03148457; Sweden:
TIMING ClinicalTrials.gov Identifier: NCT02961348; UK:
OPTIMAS: EudraCT, 2018-003859-38 and USA: START
ClinicalTrials.gov Identifier: NCT03021928).
Reinitiating oral anticoagulant after intracranial
haemorrhage
Patients with AF who survive an ICH are at increased risk of
subsequent ischaemic stroke.25 However, determining the
best approach for reducing further risk of stroke in patients
with AF and previous ICH, or other clinically relevant
bleeds, requires careful consideration of the associated
risks.30 All studies until now were done with VKAs.
Currently, several RCTs are investigating the risks and ben-
efits of start of DOAC after ICH: ENRICH-AF
(ClinicalTrials.gov Identifier: NCT03950076), SoSTART2
(ClinicalTrials.gov Identifier: NCT03153150), NASPAF-ICH
(ClinicalTrials.gov Identifier: NCT02998905), and Prestige
AF (https://clinicaltrials.gov/ct2/show/NCT03996772).
A cohort study using national registry data suggested that
oral anticoagulation was associated with a significant reduc-
tion in ischaemic stroke/all-cause mortality; therein sup-
porting the reintroduction of OACs after resolution of ICH.30
One-year follow-up data (N¼ 1752) showed that the rate of
ischaemic stroke/SE and all-cause mortality (per 100 person
years) was 13.6 with oral anticoagulants (65% VKAs, 2%
NOACs), 27.3 with no treatment, and 25.7 with antiplatelet
therapy. The aHR of ischaemic stroke/SE and all-cause mor-
tality was 0.55 (95% CI 0.39–0.78) in patients on oral antico-
agulant treatment, comparedwith those on no treatment.
The question of starting or reinitiating oral anticoagulant
(OAC) treatment in patients with AF after spontaneous ICH
also depends on the underlying aetiology. The most fre-
quent risk factor is arterial hypertension, and if adequate
blood pressure control can be achieved, the benefit of OAC
treatment in high-risk patients is likely to surpass the risk
of further ICH- which is estimated at about 2% per year.31 In
contrast, in patients with lobar ICH due to suspected cere-
bral amyloid angiopathy, the estimated risk of ICH recur-
rence is about 5–15% per year, making these patients
ineligible for OAC treatment.
More recently, the results from an observational study
have suggested that anticoagulant treatment can be initi-
ated 7–8weeks after ICH, in patients with AF to optimize
the benefit from treatment and minimize stroke risk.32 Of
2619 ICH survivors with AF, anticoagulant treatment was
associated with a reduced risk of vascular death and non-
fatal stroke in patients deemed to be high-risk yet without
any significantly increased risk of severe haemorrhage.
Noteworthy, the ESC guidelines recommend that after ICH,
oral anticoagulation in AF patients may be reinitiated after
between 4–8weeks provided the cause of bleeding or the
relevant risk factor has been treated or controlled.22
Non-vitamin K oral anticoagulants in embolic
stroke of undetermined aetiology (ESUS)
Cryptogenic ischaemic stroke describes the substantial
fraction of ischaemic strokes that are of unclear cause.
ESUS has been proposed for non-lacunar cryptogenic stroke
with a presumed embolic mechanism.33 Unrecognized par-
oxysmal AF can be identified using cardiac rhythmmonitor-
ing during follow-up of patients with cryptogenic ischaemic
stroke34,35 and suspected to have a role in recurrent stroke
in ESUS patients.33
Two large, international randomized studies tested the
hypothesis that NOACs are more effective than 100mg as-
pirin in patients with ESUS: RE-SPECT ESUS (Randomized,
Double-Blind, Evaluation in Secondary Stroke Prevention
Comparing the Efficacy and Safety of the Oral Thrombin
Inhibitor Dabigatran Etexilate vs. Acetylsalicylic Acid in
Patients with Embolic Stroke of Undetermined Source)36
and NAVIGATE ESUS (New Approach Rivaroxaban Inhibition
of Factor Xa in a Global Trial vs. ASA to Prevent Embolism in
Embolic Stroke of Undetermined Source).37 For both trials,
patients with AF or a history of AF were excluded, and par-
ticipation required at least 20h of cardiac rhythmmonitor-
ing prior to randomization to exclude AF (much longer in
many participants).36,37 Both trials were neutral for their
primary outcome of all recurrent strokes, although RE-
SPECT ESUS reported an intriguing divergence of the
Kaplan–Meier curves beginning after 1 year of follow-up
that favoured dabigatran over aspirin.36
During the mean 11-month follow-up of 7213 participants
in NAVIGATE ESUS, AF was reported in 3% of patients.37 Since
participants were not systematically screened, this is almost
certainly a substantial underestimate. At the time of
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recurrent ischaemic stroke, AF was identified in 12% (19/
153) of those assigned to aspirin and 5% (8/156) of those
assigned to rivaroxaban 15mg daily, supporting a substantial
efficacy of rivaroxaban for preventing recurrent stroke re-
lated to AF that was not apparent at the time of index
ESUS.38 Nevertheless, the investigators concluded that oc-
cult AF was not a major cause of recurrent ischaemic stroke
in NAVIGATE ESUS participants who had been screened to ex-
clude AF as part of eligibility assessment.
The RE-SPECT ESUS trial involved 5390 who were ran-
domized to either 150mg dabigatran twice daily or, if age
75years or estimated creatine clearance 50mL/min,
110mg dabigatran twice daily.36 During the mean follow-
up of 19months, 7.5% patients were reported to develop
AF.39 At the time of recurrent ischaemic stroke, AF was
identified in 15.4% (30/195) of those assigned to aspirin
and 9.6% (20/208) of those assigned to dabigatran.39
While these two trials did not demonstrate a benefit of
NOACs over aspirin for reducing recurrent stroke in unse-
lected ESUS patients, they provide information about
bleeding associated with NOACs vs. aspirin from random-
ized comparisons in large numbers of patients with recent
ischaemic stroke. Severe bleeding complications [defined
as International Society on Thrombosis and Haemostasis
(ISTH) major bleeding] in the RE-SPECT ESUS study oc-
curred at a rate of 1.7%/year in the dabigatran group and
of 1.4%/year in those assigned aspirin 100mg daily (HR
1.19, 95% CI 0.85–1.66; P¼ 0.30). In the NAVIGATE ESUS
study, the rates of ISTH major bleeding was1.8%/year
among those assigned rivaroxaban 15mg daily and 0.7%/
year among those assigned aspirin 100mg daily (HR 2.72,
95% CI 1.68–4.39; P< 0.001).4,5
In conclusion, the two trials did not show a significant
benefit of a NOAC over aspirin in ESUS patients. We hypoth-
esize that the follow-up time was too short to allow suffi-
cient numbers of participants to develop AF to
demonstrate NOAC efficacy, with early recurrent strokes
dominated by atheroembolic mechanisms.
Practical aspects
If a patient with known AF suffers a TIA or ischaemic stroke
compliance with oral anticoagulation should be evaluated.
In the majority of these patients, coagulation parameters
are normal indicating non-compliance. Another subgroup of
patients have been treated with too low a dose of a
NOAC.40,41 Due to fear of bleeding these patients are
treated with a reduced dose of a NOAC despite not fulfilling
the criteria for dose reduction. Time of resumption of anti-
coagulation depends on the severity of stroke and the size
of the ischaemic defect in brain imaging (see central figure).
The highest risk of a recurrent stroke is in the first 10days
after the initial event. Therefore, early initiation or resump-
tion of anticoagulation is warranted. In patients with a large
area of the ischaemic stroke, early anticoagulation can lead
to haemorrhagic transformation.42 Non-vitamin K oral anti-
coagulants are favoured over VKAs due to their improved ef-
ficacy and better safety, in particular concerning
intracranial bleeds. Patients with TIA or ischaemic stroke in
sinus rhythm should receive cardiac rhythm monitoring for
at least 72h to detect unrecognized paroxysmal AF. In el-
derly patients with cryptogenic stroke or ESUS long-term
electrocardiogrammonitoring is recommended.
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Erratum to: NOACs for secondary stroke prevention in patients with atrial fibrillation [European Heart Journal Supplements 2020;22:I13–I21,
doi:10.1093/eurheartj/suaa104]
In the originally published version of this manuscript, there was an error in Table 1, Patients with atrial fibrillation and prior TIA or stroke in
randomized trials: baseline data. The footnote should read: “bEdoxaban 60 mg or 30 mg in patients fulfilling the dose reduction criteria.”
instead of “bEdoxaban 60 mg.”
This has now been corrected online. The publisher apologises for the error.
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